Exponent (EXPO)
Market Price (7/22/2026): $60.63 | Market Cap: $3.0 BilSector: Industrials | Industry: Research & Consulting Services
Exponent (EXPO)
Market Price (7/22/2026): $60.63Market Cap: $3.0 BilSector: IndustrialsIndustry: Research & Consulting Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.7%, Dividend Yield is 2.0% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 19% Low stock price volatilityVol 12M is 32% Megatrend and thematic driversMegatrends include Advanced Materials, Electric Vehicles & Autonomous Driving, and Automation & Robotics. Themes include Lightweight Composites, Show more. | Weak multi-year price returns2Y Excs Rtn is -73%, 3Y Excs Rtn is -100% | Key risksEXPO key risks include [1] its dependence on attracting and retaining highly specialized personnel, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.7%, Dividend Yield is 2.0% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 19% |
| Low stock price volatilityVol 12M is 32% |
| Megatrend and thematic driversMegatrends include Advanced Materials, Electric Vehicles & Autonomous Driving, and Automation & Robotics. Themes include Lightweight Composites, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -73%, 3Y Excs Rtn is -100% |
| Key risksEXPO key risks include [1] its dependence on attracting and retaining highly specialized personnel, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 7/13/2026
Exponent (EXPO) stock has lost about 5% since 3/31/2026 because of the following key factors:
1. Strong Q1 Fiscal 2026 Performance and Optimistic Outlook
Exponent reported better-than-expected results for fiscal Q1 2026, which ended April 30, 2026, with diluted earnings per share (EPS) of $0.59, surpassing analysts' consensus by $0.03. Revenue also rose 14.3% year-over-year to $166.30 million, exceeding consensus estimates of $149.53 million. The company further provided a positive outlook, forecasting high single-digit net revenue growth and an EBITDA margin of 27.6%-28.1% for the full fiscal year 2026, suggesting continued operational strength.
2. Mixed Analyst Sentiment and Price Target Adjustments
Despite positive recent financial performance, analyst sentiment for Exponent remained mixed during the period. While some analysts maintained a "Moderate Buy" consensus, others adjusted their price targets downward in May 2026; for instance, UBS lowered its target from $85 to $75, and JP Morgan reduced its target from $95 to $80. These adjustments, alongside a consensus rating of "Hold" from some analysts, contributed to the stock's inability to break out of its stable trend.
Show more
Exponent (EXPO) stock has lost about 5% since 3/31/2026 because of the following key factors:
1. Strong Q1 Fiscal 2026 Performance and Optimistic Outlook
Exponent reported better-than-expected results for fiscal Q1 2026, which ended April 30, 2026, with diluted earnings per share (EPS) of $0.59, surpassing analysts' consensus by $0.03. Revenue also rose 14.3% year-over-year to $166.30 million, exceeding consensus estimates of $149.53 million. The company further provided a positive outlook, forecasting high single-digit net revenue growth and an EBITDA margin of 27.6%-28.1% for the full fiscal year 2026, suggesting continued operational strength.
2. Mixed Analyst Sentiment and Price Target Adjustments
Despite positive recent financial performance, analyst sentiment for Exponent remained mixed during the period. While some analysts maintained a "Moderate Buy" consensus, others adjusted their price targets downward in May 2026; for instance, UBS lowered its target from $85 to $75, and JP Morgan reduced its target from $95 to $80. These adjustments, alongside a consensus rating of "Hold" from some analysts, contributed to the stock's inability to break out of its stable trend.
Show more
Updated on 7/13/2026
Exponent (EXPO) stock has lost about 5% since 3/31/2026 because of the following key factors:
1. Strong Q1 Fiscal 2026 Performance and Optimistic Outlook
Exponent reported better-than-expected results for fiscal Q1 2026, which ended April 30, 2026, with diluted earnings per share (EPS) of $0.59, surpassing analysts' consensus by $0.03. Revenue also rose 14.3% year-over-year to $166.30 million, exceeding consensus estimates of $149.53 million. The company further provided a positive outlook, forecasting high single-digit net revenue growth and an EBITDA margin of 27.6%-28.1% for the full fiscal year 2026, suggesting continued operational strength.
2. Mixed Analyst Sentiment and Price Target Adjustments
Despite positive recent financial performance, analyst sentiment for Exponent remained mixed during the period. While some analysts maintained a "Moderate Buy" consensus, others adjusted their price targets downward in May 2026; for instance, UBS lowered its target from $85 to $75, and JP Morgan reduced its target from $95 to $80. These adjustments, alongside a consensus rating of "Hold" from some analysts, contributed to the stock's inability to break out of its stable trend.
3. Anticipation of Q2 Fiscal 2026 Results and Valuation Concerns
The stock's movement remained largely flat as investors awaited the Q2 fiscal 2026 earnings report, scheduled for release on July 30, 2026, which covers the period ending July 3, 2026. This "wait and see" approach was compounded by concerns regarding Exponent's valuation, evidenced by a high forward price-to-earnings (P/E) ratio of 31.8x, implying that much of the expected positive news may already be priced into the stock.
4. Strategic Capital Allocation and Leadership Changes
Exponent demonstrated a commitment to shareholder returns by declaring a regular quarterly dividend for Q2 fiscal 2026 and increasing its stock repurchase authorization by $50 million on April 30, 2026. Simultaneously, the company announced leadership changes on April 6, 2026, with John Pye elevated to President and Eric Anderson appointed as Chief Financial Officer. Such executive transitions can often lead to a period of investor assessment, contributing to a stable stock performance as the market evaluates the potential impact of new leadership.
Show less
Exponent (EXPO) stock has lost about 5% since 3/31/2026 because of the following key factors:
1. Strong Q1 Fiscal 2026 Performance and Optimistic Outlook
Exponent reported better-than-expected results for fiscal Q1 2026, which ended April 30, 2026, with diluted earnings per share (EPS) of $0.59, surpassing analysts' consensus by $0.03. Revenue also rose 14.3% year-over-year to $166.30 million, exceeding consensus estimates of $149.53 million. The company further provided a positive outlook, forecasting high single-digit net revenue growth and an EBITDA margin of 27.6%-28.1% for the full fiscal year 2026, suggesting continued operational strength.
2. Mixed Analyst Sentiment and Price Target Adjustments
Despite positive recent financial performance, analyst sentiment for Exponent remained mixed during the period. While some analysts maintained a "Moderate Buy" consensus, others adjusted their price targets downward in May 2026; for instance, UBS lowered its target from $85 to $75, and JP Morgan reduced its target from $95 to $80. These adjustments, alongside a consensus rating of "Hold" from some analysts, contributed to the stock's inability to break out of its stable trend.
3. Anticipation of Q2 Fiscal 2026 Results and Valuation Concerns
The stock's movement remained largely flat as investors awaited the Q2 fiscal 2026 earnings report, scheduled for release on July 30, 2026, which covers the period ending July 3, 2026. This "wait and see" approach was compounded by concerns regarding Exponent's valuation, evidenced by a high forward price-to-earnings (P/E) ratio of 31.8x, implying that much of the expected positive news may already be priced into the stock.
4. Strategic Capital Allocation and Leadership Changes
Exponent demonstrated a commitment to shareholder returns by declaring a regular quarterly dividend for Q2 fiscal 2026 and increasing its stock repurchase authorization by $50 million on April 30, 2026. Simultaneously, the company announced leadership changes on April 6, 2026, with John Pye elevated to President and Eric Anderson appointed as Chief Financial Officer. Such executive transitions can often lead to a period of investor assessment, contributing to a stable stock performance as the market evaluates the potential impact of new leadership.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -6.5% change in EXPO stock from 3/31/2026 to 7/21/2026 was primarily driven by a -9.9% change in the company's P/E Multiple.| (LTM values as of) | 3312026 | 7212026 | Change |
|---|---|---|---|
| Stock Price ($) | 64.91 | 60.66 | -6.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 582 | 603 | 3.6% |
| Net Income Margin (%) | 18.2% | 18.1% | -0.8% |
| P/E Multiple | 30.8 | 27.7 | -9.9% |
| Shares Outstanding (Mil) | 50 | 50 | 1.0% |
| Cumulative Contribution | -6.5% |
Market Drivers
3/31/2026 to 7/21/2026| Return | Correlation | |
|---|---|---|
| EXPO | -6.5% | |
| Market (SPY) | 15.1% | -1.7% |
| Sector (XLI) | 10.5% | 1.0% |
Fundamental Drivers
The -11.8% change in EXPO stock from 12/31/2025 to 7/21/2026 was primarily driven by a -17.0% change in the company's P/E Multiple.| (LTM values as of) | 12312025 | 7212026 | Change |
|---|---|---|---|
| Stock Price ($) | 68.81 | 60.66 | -11.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 571 | 603 | 5.5% |
| Net Income Margin (%) | 18.3% | 18.1% | -1.5% |
| P/E Multiple | 33.4 | 27.7 | -17.0% |
| Shares Outstanding (Mil) | 51 | 50 | 2.2% |
| Cumulative Contribution | -11.8% |
Market Drivers
12/31/2025 to 7/21/2026| Return | Correlation | |
|---|---|---|
| EXPO | -11.8% | |
| Market (SPY) | 10.0% | 18.9% |
| Sector (XLI) | 15.5% | 15.1% |
Fundamental Drivers
The -17.4% change in EXPO stock from 6/30/2025 to 7/21/2026 was primarily driven by a -22.3% change in the company's P/E Multiple.| (LTM values as of) | 6302025 | 7212026 | Change |
|---|---|---|---|
| Stock Price ($) | 73.41 | 60.66 | -17.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 559 | 603 | 7.8% |
| Net Income Margin (%) | 18.9% | 18.1% | -4.2% |
| P/E Multiple | 35.7 | 27.7 | -22.3% |
| Shares Outstanding (Mil) | 51 | 50 | 3.0% |
| Cumulative Contribution | -17.4% |
Market Drivers
6/30/2025 to 7/21/2026| Return | Correlation | |
|---|---|---|
| EXPO | -17.4% | |
| Market (SPY) | 22.1% | 21.7% |
| Sector (XLI) | 22.4% | 22.6% |
Fundamental Drivers
The -32.1% change in EXPO stock from 6/30/2023 to 7/21/2026 was primarily driven by a -38.2% change in the company's P/E Multiple.| (LTM values as of) | 6302023 | 7212026 | Change |
|---|---|---|---|
| Stock Price ($) | 89.38 | 60.66 | -32.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 525 | 603 | 14.8% |
| Net Income Margin (%) | 19.4% | 18.1% | -6.8% |
| P/E Multiple | 44.9 | 27.7 | -38.2% |
| Shares Outstanding (Mil) | 51 | 50 | 2.7% |
| Cumulative Contribution | -32.1% |
Market Drivers
6/30/2023 to 7/21/2026| Return | Correlation | |
|---|---|---|
| EXPO | -32.1% | |
| Market (SPY) | 74.8% | 32.4% |
| Sector (XLI) | 73.4% | 37.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| EXPO Return | 31% | -14% | -10% | 2% | -21% | -9% | -26% |
| Peers Return | 42% | -3% | 19% | 9% | -13% | -10% | 40% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 98% |
Monthly Win Rates [3] | |||||||
| EXPO Win Rate | 58% | 42% | 50% | 75% | 33% | 71% | |
| Peers Win Rate | 63% | 52% | 55% | 63% | 52% | 57% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 43% | |
Max Drawdowns [4] | |||||||
| EXPO Max Drawdown | -16% | -30% | -36% | -23% | -30% | -32% | |
| Peers Max Drawdown | -14% | -25% | -15% | -20% | -30% | -33% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TTEK, J, ACM, ICFI, FCN. See EXPO Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/21/2026 (YTD)
How Low Can It Go
| Event | EXPO | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -25.5% | -9.5% |
| % Gain to Breakeven | 34.3% | 10.5% |
| Time to Breakeven | 177 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -18.7% | -6.7% |
| % Gain to Breakeven | 23.0% | 7.1% |
| Time to Breakeven | 427 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -30.4% | -24.5% |
| % Gain to Breakeven | 43.7% | 32.4% |
| Time to Breakeven | 837 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.8% | -33.7% |
| % Gain to Breakeven | 38.4% | 50.9% |
| Time to Breakeven | 99 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -11.1% | -19.2% |
| % Gain to Breakeven | 12.5% | 23.8% |
| Time to Breakeven | 24 days | 105 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -19.5% | -17.9% |
| % Gain to Breakeven | 24.3% | 21.8% |
| Time to Breakeven | 64 days | 123 days |
In The Past
Exponent's stock fell 0.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | EXPO | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -25.5% | -9.5% |
| % Gain to Breakeven | 34.3% | 10.5% |
| Time to Breakeven | 177 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -30.4% | -24.5% |
| % Gain to Breakeven | 43.7% | 32.4% |
| Time to Breakeven | 837 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.8% | -33.7% |
| % Gain to Breakeven | 38.4% | 50.9% |
| Time to Breakeven | 99 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -30.0% | -53.4% |
| % Gain to Breakeven | 42.8% | 114.4% |
| Time to Breakeven | 74 days | 1085 days |
In The Past
Exponent's stock fell 0.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Exponent (EXPO)
Exponent, Inc. (EXPO) operates as a global science and engineering consulting company. The firm specializes in providing expert analysis and solutions to solve complex technical and scientific challenges facing a diverse range of stakeholders. They apply deep expertise across approximately 90 technical disciplines to help clients understand, prevent, and resolve intricate issues.
The company's main services are delivered through two key segments. The Engineering and Other Scientific segment encompasses a broad array of fields such as biomechanics, civil and mechanical engineering, data sciences, electrical engineering, human factors, and materials science. The Environmental and Health segment focuses on areas like chemical regulation, food safety, ecological and biological sciences, and health sciences, offering critical insights into environmental and health-related concerns.
Exponent serves a wide array of primary customers and markets globally. Their clientele spans various sectors including chemical, construction, consumer products, energy, food and beverage, government, life sciences, insurance, manufacturing, technology, industrial equipment, and transportation. This diverse client base highlights their versatile application of scientific and engineering principles to address critical problems across the economy.
AI Analysis | Feedback
Here are 1-3 brief analogies for Exponent (EXPO):
- Exponent is like **McKinsey or Boston Consulting Group, but for highly specialized scientific and engineering challenges.**
- Think of Exponent as the **Mayo Clinic for complex industrial and scientific problems** that require deep expert analysis.
AI Analysis | Feedback
- Engineering and Scientific Consulting: Provides expert consulting services across various engineering and scientific disciplines, including biomechanics, civil, electrical, mechanical, and data sciences, to solve complex technical challenges.
- Environmental and Health Consulting: Offers specialized consulting services in areas such as chemical regulation, food safety, ecological sciences, and environmental and public health matters.
AI Analysis | Feedback
Exponent, Inc. (EXPO) primarily sells its science and engineering consulting services to other companies, government entities, and various organizations, rather than to individuals.
Due to the nature of its diversified consulting business, Exponent typically serves a broad range of clients across numerous industries, and its public filings generally indicate that no single client accounts for a significant percentage of its consolidated revenues (e.g., 10% or more). Therefore, specific "major customer companies" by name are not publicly disclosed.
However, Exponent identifies its customer base by the sectors it serves. These major client categories include:
- Chemical
- Construction
- Consumer Products
- Energy
- Food, Beverage and Nutrition
- Government
- Life Sciences
- Insurance
- Manufacturing
- Technology
- Industrial Equipment
- Transportation
AI Analysis | Feedback
null
AI Analysis | Feedback
Catherine Corrigan, Ph.D.
President and Chief Executive Officer
Dr. Catherine Corrigan joined Exponent in 1996, focusing on the biomechanics of human injury. She was appointed President of the company in 2016 and Chief Executive Officer in 2018. Prior to her role as CEO, she held positions as Principal in the Biomechanics Practice, Corporate Vice President, and Vice President of Exponent's Transportation Group. She holds a Ph.D. in Medical Engineering from the Harvard-MIT Division of Health Sciences and Technology, an M.S. in Mechanical Engineering from MIT, and a B.S. in Bioengineering from the University of Pennsylvania. Before joining Exponent, Dr. Corrigan was a researcher at the Orthopedic Biomechanics Laboratory of Beth Israel Hospital and Harvard Medical School.
Richard Schlenker
Executive Vice President and Chief Financial Officer
Mr. Richard Schlenker joined Exponent in October 1990. He has served in various finance and accounting positions within the company, including Business Manager for Exponent Failure Analysis Associates, Manager of Corporate Development, and Director of Corporate Development. He was appointed Corporate Secretary in November 1997 and became Chief Financial Officer in July 1999. Mr. Schlenker holds a B.S. in Finance from the University of Southern California.
Brian Kundert
Chief Human Resources Officer
Mr. Brian Kundert serves as the Chief Human Resources Officer for Exponent.
Subbaiah Malladi, Ph.D., P.E.
Chief Technical Officer and Principal Engineer
Dr. Subbaiah Malladi has been the Chief Technical Officer of Exponent Inc. since October 1998. He also serves as a Principal Engineer.
Ellen Donovan, MPH
Vice President, Business Development
Ms. Ellen Donovan holds the position of Vice President, Business Development at Exponent.
AI Analysis | Feedback
The key risks to Exponent, Inc. (symbol: EXPO) are primarily centered around its human capital, the competitive landscape of the consulting industry, and its revenue concentration in specific sectors.
- Reliance on Highly Skilled Personnel: Exponent's business model is fundamentally dependent on its ability to attract and retain a substantial workforce of highly skilled scientists and engineers, many of whom hold advanced degrees. The company reported employing 949 technical staff, with 731 holding doctorates as of January 2, 2026. A failure to attract and retain these critical employees could significantly impair the company's ability to deliver its specialized consulting services.
- Increasing Competition: The consulting market in which Exponent operates is characterized by high competition and relatively low barriers to entry. The company acknowledges growing competition, including from new entrants leveraging artificial intelligence technologies. This competitive environment can exert pressure on Exponent to continuously innovate, maintain service quality, and manage pricing effectively.
- Dependence on Key Industries and Volatile Demand: While Exponent serves a diverse range of sectors, a significant portion of its revenue is concentrated in a few key industries. In 2025, the consumer products, energy and utilities, transportation, and chemical industries collectively accounted for 68% of its total revenues, exposing the company to sector-specific risks and market fluctuations. Additionally, the demand for Exponent's services can be volatile and event-driven, which may lead to fluctuations in engagement timing and revenue.
AI Analysis | Feedback
null
AI Analysis | Feedback
Exponent, Inc. (symbol: EXPO) operates in diverse science and engineering consulting sectors. The addressable markets for its main products and services can be estimated as follows:
Engineering and Other Scientific Segment
-
Overall Engineering Consulting Services:
- The global engineering consulting services market was valued at approximately USD 202.8 billion in 2025 and is projected to reach USD 296.2 billion by 2035, growing at a Compound Annual Growth Rate (CAGR) of 4.3% from 2026 to 2035.
- Another estimate for the global engineering services market size indicated USD 2.34 trillion in 2025, with a projection to grow to USD 5.37 trillion by 2034, exhibiting a CAGR of 10.60% from 2026 to 2034.
- North America is a dominant region within this market, anticipated to capture 39.5% of the global engineering consulting services market by 2035.
-
Biomedical Engineering/Bioengineering Technology:
- The global Bioengineering Technology Market, which includes biomedical engineering, was valued at USD 301.53 billion in 2024 and is expected to reach approximately USD 762.73 billion by 2032, growing at a CAGR of 12.3% from 2025 to 2032.
-
Medical Device Engineering Services:
- The global medical device engineering services market is estimated to be valued at USD 6.30 billion in 2025 and is expected to reach USD 13.68 billion by 2032, exhibiting a CAGR of 11.7% from 2025 to 2032.
- Another source valued the global medical device engineering market at US$9.0 billion in 2024, projected to advance at a CAGR of 10.1% from 2024 to 2029, reaching US$14.7 billion by the end of the period.
- North America is expected to maintain its leadership, holding 35.2% of the market share in 2025.
-
Human Biomechanics Analysis Software:
- The global human biomechanics analysis software market size is estimated to be USD 350 million in 2024, projected to reach approximately USD 600 million by 2029, representing a CAGR of around 12%.
- Another estimate places the market at USD 500 million in 2025, projected to reach approximately USD 1.5 billion by 2033, with a CAGR of 15% from 2025 to 2033.
- North America currently holds the largest share in this market.
Environmental and Health Segment
-
Environmental Consulting Services:
- The global environmental consulting services market was valued at US$ 43.04 billion in 2023 and is anticipated to reach US$ 77.35 billion by 2031, growing at a CAGR of 7.6% from 2023 to 2031.
- Another report estimated the global environmental consulting services market size at USD 43.20 billion in 2024, predicted to increase to USD 92.85 billion by 2034, expanding at a CAGR of 7.95% from 2025 to 2034.
- North America is expected to continue its dominance in the environmental consulting services market, holding a 35.53% revenue share in 2025.
-
Healthcare Consulting Services:
- The global healthcare consulting services market was estimated at USD 28.19 billion in 2023 and is projected to reach USD 51.98 billion by 2030, growing at a CAGR of 9.33% from 2024 to 2030.
- Another estimate places the global healthcare consulting services market size at USD 36.44 billion in 2025, predicted to increase to approximately USD 79.41 billion by 2035, expanding at a CAGR of 8.10% from 2026 to 2035.
- North America dominated the healthcare consulting services market, holding 38.14% of the market share in 2023. In 2025, North America accounted for 48% of the revenue share.
-
Life Sciences Consulting Market:
- The global Life Sciences Consulting Market size is expected to grow from USD 34.75 billion in 2025 to USD 38.02 billion in 2026 and is forecast to reach USD 59.64 billion by 2031, at a 9.42% CAGR from 2026 to 2031.
- The global life science consulting market size was calculated at US$ 34.82 billion in 2024, grew to US$ 38.08 billion in 2025, and is projected to reach around US$ 84.83 billion by 2034.
- North America dominated the life science consulting market in 2024.
AI Analysis | Feedback
Exponent (EXPO) is expected to drive future revenue growth over the next 2-3 years through several key factors:
- Consistent High-Single-Digit Revenue Growth and Price Increases: Management anticipates high-single-digit revenue growth for fiscal year 2026 and beyond, with expectations of reaching low double-digit growth in subsequent years. Additionally, Exponent projects realized rate increases of 3% to 3.5% for the first quarter and full year 2026.
- Growing Demand in Strategic Sectors and Macro Trends: The company is strategically positioned to capitalize on increasing demand across several industries and macro trends. Key drivers include the transportation sector (automation and electrification), the utilities sector (grid modernization, wildfire mitigation, aging infrastructure, and increased energy demand fueled by AI and data center investments), and consumer electronics (product safety, sustainability, and AI-driven product development). Furthermore, opportunities in life sciences and chemicals are expected to contribute to growth due to ongoing needs for safety, health, and environmental consulting services.
- Headcount Expansion and Optimized Utilization Rates: Exponent achieved approximately 4% headcount growth in 2025 and demonstrated improved utilization rates in Q4 2025, indicating an effective alignment of resources with market demand. The company aims for a long-term target of sustained mid-70s utilization, which is expected to enhance operational efficiency and support revenue expansion.
- Leveraging Multidisciplinary Expertise and Proactive Consulting Services: Exponent's distinctive ability to assemble specialized multidisciplinary teams to address complex challenges, coupled with an increased focus on proactive risk management and advisory services, particularly in the utility sector and through AI-related consulting, is a significant growth driver. This strategic emphasis on its unique expertise and forward-looking solutions strengthens its competitive advantage and expands its service offerings.
AI Analysis | Feedback
Capital Allocation Decisions (Last 3-5 Years) for Exponent (EXPO)
Share Repurchases
- Exponent's Board of Directors authorized an additional $100 million for its share repurchase program in October 2025, bringing the total available for future repurchases to $121.6 million as of October 3, 2025.
- During fiscal year 2025, Exponent repurchased $97.8 million of common stock.
- In the first half of 2025, the company repurchased $32.7 million of common stock, including $27.7 million in the second quarter alone.
Share Issuance
- A company Vice President converted 5,934 vested Restricted Stock Units (RSUs) into common stock on March 11, 2026, with 2,384 shares subsequently withheld by the company to cover tax obligations.
- The number of common shares outstanding decreased from 52,116,161 as of February 18, 2022, to 50,642,422 as of February 17, 2023, indicating a net reduction in outstanding shares over that period.
Capital Expenditures
- Capital expenditures for the full year 2025 were expected to be between $10 million and $12 million.
- In the second quarter of 2025, capital expenditures amounted to $2.3 million.
- The purchase of property, plant, and equipment was approximately $2.69 million in the fourth quarter of 2025.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 71.97 |
| Mkt Cap | 6.3 |
| Rev LTM | 4,502 |
| Op Inc LTM | 496 |
| FCF LTM | 333 |
| FCF 3Y Avg | 304 |
| CFO LTM | 431 |
| CFO 3Y Avg | 338 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 2.6% |
| Rev Chg 3Y Avg | 6.8% |
| Rev Chg Q | 5.1% |
| QoQ Delta Rev Chg LTM | 1.2% |
| Op Inc Chg LTM | -1.4% |
| Op Inc Chg 3Y Avg | 10.4% |
| Op Mgn LTM | 9.0% |
| Op Mgn 3Y Avg | 9.0% |
| QoQ Delta Op Mgn LTM | -0.4% |
| CFO/Rev LTM | 8.7% |
| CFO/Rev 3Y Avg | 7.6% |
| FCF/Rev LTM | 7.4% |
| FCF/Rev 3Y Avg | 6.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 6.3 |
| P/S | 1.2 |
| P/Op Inc | 12.5 |
| P/EBIT | 12.0 |
| P/E | 17.8 |
| P/CFO | 15.6 |
| Total Yield | 6.1% |
| Dividend Yield | 0.9% |
| FCF Yield 3Y Avg | 4.3% |
| D/E | 0.3 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 7.0% |
| 3M Rtn | -7.1% |
| 6M Rtn | -15.7% |
| 12M Rtn | -11.3% |
| 3Y Rtn | -19.8% |
| 1M Excs Rtn | 6.8% |
| 3M Excs Rtn | -12.7% |
| 6M Excs Rtn | -26.0% |
| 12M Excs Rtn | -31.4% |
| 3Y Excs Rtn | -86.2% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Engineering and Other Scientific | 494 | 470 | 447 | 428 |
| Environmental and Health | 88 | 89 | 90 | 85 |
| Total | 582 | 559 | 537 | 513 |
| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Engineering and Other Scientific | 174 | 165 | 154 | 153 |
| Environmental and Health | 31 | 30 | 28 | 27 |
| Corporate operating expense | -84 | -75 | -71 | -39 |
| Total | 120 | 120 | 111 | 141 |
| $ Mil | 2006 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|
| Other Scientific and Engineering | 63 | 47 | 45 | 49 | 49 |
| Environmental And Health | 12 | 13 | 12 | 13 | 10 |
| Corporate | 45 | 33 | |||
| Total | 75 | 60 | 57 | 107 | 91 |
Price Behavior
Price Behavior
| Market Price | $60.66 | |
| Market Cap ($ Bil) | 3.0 | |
| First Trading Date | 08/17/1990 | |
| Distance from 52W High | -23.3% | |
| 50 Days | 200 Days | |
| DMA Price | $58.79 | $66.65 |
| DMA Trend | down | down |
| Distance from DMA | 3.2% | -9.0% |
| 3M | 1YR | |
| Volatility | 35.3% | 31.7% |
| Downside Capture | -25.15 | 76.90 |
| Upside Capture | -67.47 | 43.28 |
| Correlation (SPY) | -7.3% | 22.0% |
EXPO Betas & Captures as of 6/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.04 | -0.18 | 0.06 | 0.59 | 0.60 | 0.68 |
| Up Beta | 0.21 | 0.38 | 0.37 | 0.90 | 0.91 | 0.72 |
| Down Beta | -0.23 | -0.18 | -0.39 | 0.01 | -0.03 | 0.29 |
| Up Capture | 4% | -64% | -16% | 35% | 39% | 37% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 11 | 17 | 28 | 54 | 117 | 356 |
| Down Capture | -11% | 5% | 30% | 98% | 99% | 101% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 10 | 24 | 34 | 70 | 134 | 394 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EXPO | |
|---|---|---|---|---|
| EXPO | -14.9% | 31.7% | -0.48 | - |
| Sector ETF (XLI) | 19.3% | 16.6% | 0.88 | 22.0% |
| Equity (SPY) | 20.3% | 12.6% | 1.19 | 21.3% |
| Gold (GLD) | 21.6% | 28.1% | 0.69 | 3.2% |
| Commodities (DBC) | 31.4% | 19.1% | 1.30 | -7.8% |
| Real Estate (VNQ) | 15.0% | 14.0% | 0.76 | 28.3% |
| Bitcoin (BTCUSD) | -44.6% | 42.9% | -1.25 | 17.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EXPO | |
|---|---|---|---|---|
| EXPO | -6.5% | 30.2% | -0.19 | - |
| Sector ETF (XLI) | 13.4% | 17.6% | 0.59 | 46.7% |
| Equity (SPY) | 12.9% | 17.1% | 0.58 | 43.7% |
| Gold (GLD) | 17.3% | 18.4% | 0.76 | 4.6% |
| Commodities (DBC) | 8.9% | 19.5% | 0.35 | 5.0% |
| Real Estate (VNQ) | 2.9% | 18.9% | 0.05 | 47.6% |
| Bitcoin (BTCUSD) | 14.9% | 53.4% | 0.46 | 20.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EXPO | |
|---|---|---|---|---|
| EXPO | 8.7% | 29.0% | 0.34 | - |
| Sector ETF (XLI) | 13.9% | 20.0% | 0.61 | 49.9% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 49.9% |
| Gold (GLD) | 11.2% | 16.1% | 0.57 | 4.1% |
| Commodities (DBC) | 7.2% | 17.9% | 0.32 | 13.1% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.21 | 46.8% |
| Bitcoin (BTCUSD) | 58.7% | 66.2% | 0.99 | 14.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/3/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/30/2026 | -2.4% | -5.2% | -9.7% |
| 2/5/2026 | 12.6% | -5.2% | 1.9% |
| 10/30/2025 | 6.0% | 6.6% | 9.6% |
| 7/31/2025 | -0.9% | 3.3% | 3.5% |
| 5/1/2025 | -1.3% | -0.8% | -0.9% |
| 2/6/2025 | 1.2% | 0.7% | -6.0% |
| 10/24/2024 | -8.9% | -11.3% | -7.8% |
| 7/25/2024 | -0.6% | -1.4% | 0.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 10 | 11 |
| # Negative | 13 | 14 | 13 |
| Median Positive | 3.6% | 5.5% | 9.4% |
| Median Negative | -4.4% | -5.2% | -5.2% |
| Max Positive | 19.5% | 16.0% | 20.8% |
| Max Negative | -14.4% | -13.1% | -12.5% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/30/2026 | -2.4% | -5.2% | -9.7% |
| 2/5/2026 | 12.6% | -5.2% | 1.9% |
| 10/30/2025 | 6.0% | 6.6% | 9.6% |
| 7/31/2025 | -0.9% | 3.3% | 3.5% |
| 5/1/2025 | -1.3% | -0.8% | -0.9% |
| 2/6/2025 | 1.2% | 0.7% | -6.0% |
| 10/24/2024 | -8.9% | -11.3% | -7.8% |
| 7/25/2024 | -0.6% | -1.4% | 0.2% |
| 4/25/2024 | 19.5% | 16.0% | 20.8% |
| 2/1/2024 | -12.8% | -12.6% | -9.1% |
| 10/26/2023 | -14.4% | -13.0% | -9.3% |
| 7/27/2023 | -4.9% | -5.2% | -3.3% |
| 4/27/2023 | -4.4% | -8.4% | -4.5% |
| 2/2/2023 | 5.5% | -1.0% | -1.0% |
| 10/27/2022 | 3.6% | 5.8% | 11.1% |
| 7/28/2022 | 2.2% | 0.3% | -0.5% |
| 4/28/2022 | -7.8% | -13.1% | -12.5% |
| 2/3/2022 | -8.7% | -8.0% | 3.7% |
| 10/28/2021 | -0.4% | 2.2% | 2.2% |
| 7/29/2021 | 6.9% | 14.0% | 15.7% |
| 4/29/2021 | 0.1% | -1.3% | -5.2% |
| 2/4/2021 | 2.1% | 7.2% | 9.4% |
| 10/29/2020 | -2.8% | 5.2% | 15.9% |
| 7/30/2020 | 0.7% | -1.0% | -1.3% |
| SUMMARY STATS | |||
| # Positive | 11 | 10 | 11 |
| # Negative | 13 | 14 | 13 |
| Median Positive | 3.6% | 5.5% | 9.4% |
| Median Negative | -4.4% | -5.2% | -5.2% |
| Max Positive | 19.5% | 16.0% | 20.8% |
| Max Negative | -14.4% | -13.1% | -12.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/08/2026 | 10-Q |
| 12/31/2025 | 02/27/2026 | 10-K |
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/08/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 02/28/2025 | 10-K |
| 09/30/2024 | 11/01/2024 | 10-Q |
| 06/30/2024 | 08/02/2024 | 10-Q |
| 03/31/2024 | 05/03/2024 | 10-Q |
| 12/31/2023 | 02/23/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/05/2023 | 10-Q |
| 12/31/2022 | 02/24/2023 | 10-K |
| 09/30/2022 | 11/04/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/08/2026 | 10-Q |
| 12/31/2025 | 02/27/2026 | 10-K |
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/08/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 02/28/2025 | 10-K |
| 09/30/2024 | 11/01/2024 | 10-Q |
| 06/30/2024 | 08/02/2024 | 10-Q |
| 03/31/2024 | 05/03/2024 | 10-Q |
| 12/31/2023 | 02/23/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/05/2023 | 10-Q |
| 12/31/2022 | 02/24/2023 | 10-K |
| 09/30/2022 | 11/04/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| 03/31/2022 | 05/06/2022 | 10-Q |
| 12/31/2021 | 02/25/2022 | 10-K |
| 09/30/2021 | 11/05/2021 | 10-Q |
| 06/30/2021 | 08/06/2021 | 10-Q |
| 03/31/2021 | 05/07/2021 | 10-Q |
| 12/31/2020 | 02/26/2021 | 10-K |
| 09/30/2020 | 11/06/2020 | 10-Q |
| 06/30/2020 | 08/10/2020 | 10-Q |
| 03/31/2020 | 05/08/2020 | 10-Q |
| 12/31/2019 | 02/28/2020 | 10-K |
| 09/30/2019 | 11/01/2019 | 10-Q |
| 06/30/2019 | 08/02/2019 | 10-Q |
Recent Forward Guidance
Updated 7/12/2026Latest: Q1 2026 Earnings Reported 4/30/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q2 2026 Revenues before reimbursements growth | 7.0% | 7.0% | 0.0% | Same New | Actual: 7.0% for Q1 2026 | ||
| Q2 2026 EBITDA margin | 27.0% | 27.4% | 27.8% | -0.6% | Lower New | Actual: 28.0% for Q1 2026 | |
| 2026 Revenues before reimbursements growth | 7.0% | 7.0% | 0.0% | Affirmed | Guidance: 7.0% for 2026 | ||
| 2026 EBITDA margin | 27.6% | 27.85% | 28.1% | 0.0% | Affirmed | Guidance: 27.85% for 2026 | |
Prior: Q4 2025 Earnings Reported 2/5/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Revenue Growth | 7.0% | ||||||
| Q1 2026 EBITDA Margin | 27.5% | 28.0% | 28.5% | ||||
| 2026 Revenue Growth | 7.0% | 5.0% | Higher New | Actual: 2.0% for 2025 | |||
| 2026 EBITDA Margin | 27.6% | 27.85% | 28.1% | 0.3% | Higher New | Actual: 27.53% for 2025 | |
Q3 2025 Earnings Reported 10/30/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q4 2025 Revenue Growth | 1.0% | 4.0% | -1.0% | Lowered | Guidance: 5.0% for Q3 2025 | ||
| Q4 2025 EBITDA Margin | 26.0% | 26.5% | 27.0% | -0.8% | Lowered | Guidance: 27.25% for Q3 2025 | |
| 2025 Revenue Growth | 1.0% | 2.0% | 0.0% | Affirmed | Guidance: 2.0% for 2025 | ||
| 2025 EBITDA Margin | 27.4% | 27.53% | 27.65% | 0.8% | Raised | Guidance: 26.75% for 2025 | |
Insider Activity
Updated 7/17/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Corrigan, Catherine | Chief Executive Officer | Direct | Sell | 7172026 | 62.78 | 1,737 | 109,045 | 7,267,826 | Form |
| 2 | Corrigan, Catherine | President & CEO | Direct | Sell | 6172026 | 57.13 | 4,119 | 235,303 | 6,093,662 | Form |
| 3 | James, Bradley A | Group Vice President | Direct | Sell | 5272026 | 57.47 | 2,000 | 114,930 | 63,499 | Form |
| 4 | Reiss, Richard | Group Vice President | Direct | Sell | 5192026 | 58.65 | 1,672 | 98,062 | 134,190 | Form |
| 5 | Corrigan, Catherine | President & CEO | Direct | Sell | 5152026 | 54.06 | 4,194 | 226,726 | 5,688,032 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Corrigan, Catherine | Chief Executive Officer | Direct | Sell | 7172026 | 62.78 | 1,737 | 109,045 | 7,267,826 | Form |
| 2 | Corrigan, Catherine | President & CEO | Direct | Sell | 6172026 | 57.13 | 4,119 | 235,303 | 6,093,662 | Form |
| 3 | James, Bradley A | Group Vice President | Direct | Sell | 5272026 | 57.47 | 2,000 | 114,930 | 63,499 | Form |
| 4 | Reiss, Richard | Group Vice President | Direct | Sell | 5192026 | 58.65 | 1,672 | 98,062 | 134,190 | Form |
| 5 | Corrigan, Catherine | President & CEO | Direct | Sell | 5152026 | 54.06 | 4,194 | 226,726 | 5,688,032 | Form |
| 6 | Rakow, Joseph | Group Vice President | Direct | Sell | 5132026 | 54.66 | 2,945 | Form | ||
| 7 | Sala, Joseph | Group Vice President | Direct | Sell | 5132026 | 56.66 | 2,066 | Form | ||
| 8 | Corrigan, Catherine | President & CEO | Direct | Sell | 4162026 | 67.70 | 3,909 | 264,625 | 7,018,492 | Form |
| 9 | Corrigan, Catherine | President & CEO | Direct | Sell | 4162026 | 67.49 | 3,912 | 264,014 | 6,882,514 | Form |
| 10 | Corrigan, Catherine | President & CEO | Direct | Sell | 2182026 | 67.15 | 3,920 | 263,240 | 6,294,314 | Form |
| 11 | Pye, John | VP Global Offices & Innovation | Direct | Sell | 2122026 | 75.97 | 4,000 | 303,898 | 1,914,859 | Form |
| 12 | Corrigan, Catherine | President & CEO | Direct | Sell | 1202026 | 72.52 | 1,663 | 120,594 | 6,723,883 | Form |
| 13 | Corrigan, Catherine | President & CEO | Direct | Sell | 12162025 | 70.74 | 3,225 | 228,132 | 5,951,530 | Form |
| 14 | Corrigan, Catherine | President & CEO | Direct | Sell | 11182025 | 70.39 | 4,900 | 344,898 | 5,872,354 | Form |
| 15 | Corrigan, Catherine | President & CEO | Direct | Sell | 10162025 | 66.82 | 4,930 | 329,440 | 5,529,855 | Form |
| 16 | Corrigan, Catherine | President & CEO | Direct | Sell | 9162025 | 69.91 | 4,905 | 342,903 | 5,785,161 | Form |
| 17 | Corrigan, Catherine | President & CEO | Direct | Sell | 8152025 | 71.09 | 4,896 | 348,043 | 5,782,370 | Form |
| 18 | Sala, Joseph | Group Vice President | Direct | Sell | 8132025 | 70.64 | 1,595 | Form |
Investor Activity (13F)
Updated Jul 22, 202613F holdings as of Mar 31, 2026 (Q1 2026)
Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
Industry Resources
| Industrials Resources |
| IndustryWeek |
| Manufacturing.net |
| Aviation Week |
| Research & Consulting Services Resources |
| Consultancy.org |
| Gartner Research |
| Forrester Insights |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 7/21/2026